Article
Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
Lung cancer (Amsterdam, Netherlands) - 1 May 2020
Kneuertz Peter J, Carbone David P, D'Souza Desmond M, Shilo Konstantin, Abdel-Rasoul Mahmoud, Zhao Weiqiang, Williams Terrance M, Jones Daniel, Merritt Robert E
Abstract excerpt
OBJECTIVES: This study aimed to evaluate the prognostic and potential therapeutic value of expanded molecular testing of resected early-stage lung ACA. METHODS: We analyzed 324 patients who underwent lobectomy and lymphadenectomy for clinical Stage I&II lung ACA between 2011-2017. Molecular testing was routinely performed, first by PCR-based Sanger sequencing and FISH and then expanded to a 20 and then 50-gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
